SCHEMBL2003288

SCHEMBL2003288

O=S(=O)(Cl)c1ccc(Cl)cc1C(F)(F)F

nearest known ligand 0.60

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TRPV4 Q9HBA0 3/20 0.60
RAB9A P51151 2/20 0.51
PKM P14618 1/20 0.51
CNR2 P34972 6/20 0.43
CCR2 P41597 3/20 0.43
HSD11B1 P28845 1/20 0.42
POLB P06746 1/20 0.41
CRHBP P24387 1/20 0.41
CRHR2 Q13324 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C19 P33261 1/20 0.41
CNR1 P21554 2/20 0.40
SLC22A12 Q96S37 2/20 0.40
MCL1 Q07820 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30161661 1.00 TRPV4 (0.60) TRPV4RAB9APKMCNR2CCR2
SCHEMBL3410514 0.85 TRPV4 (0.47) TRPV4RAB9APKMCNR2CCR2
SCHEMBL27872317 0.83 RAB9A (0.50) TRPV4RAB9APKMCNR2CCR2
SCHEMBL3923293 0.83 CA12 (0.53) TRPV4RAB9APKMCNR2CCR2
SCHEMBL30395525 0.81 TRPV4 (0.60) TRPV4RAB9APKMCNR2HSD11B1
SCHEMBL3611597 0.81 TRPV4 (0.60) TRPV4RAB9APKMMCL1
SCHEMBL695151 0.81 TRPV4 (0.60) TRPV4RAB9APKMCNR2HSD11B1
SCHEMBL29374110 0.81 TRPV4 (0.60) TRPV4RAB9APKMMCL1
SCHEMBL695564 0.79 TRPV4 (0.58) TRPV4RAB9APKMHSD11B1SLC22A12
SCHEMBL29843259 0.79 TRPV4 (0.58) TRPV4RAB9APKMHSD11B1SLC22A12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630529-B2 GCN2 modulator compounds Alesta Therapeutics BV (NL) 2026-05-19 US disclosed
US-20230143059-A1 GCN2 MODULATOR COMPOUNDS Alesta Therapeutics BV (NL) 2023-05-11 US disclosed
US-20230143059-A1 GCN2 MODULATOR COMPOUNDS Alesta Therapeutics BV (NL) 2023-05-11 US disclosed
US-20230143059-A1 GCN2 MODULATOR COMPOUNDS Alesta Therapeutics BV (NL) 2023-05-11 US disclosed
CN-115768750-A GCN2 modulator compounds 阿莱斯塔治疗公司 2023-03-07 CN disclosed
US-11236055-B2 Non-systemic TGR5 agonists Venenum Biodesign, LLC (US) 2022-02-01 US disclosed
US-20200308122-A1 NOVEL NON-SYSTEMIC TGR5 AGONISTS Venenum Biodesign, LLC (US) 2020-10-01 US disclosed
US-7968567-B2 Compounds for the modulation of PPARγ activity AMGEN INC. (US) 2011-06-28 US disclosed
US-7960408-B2 Quinolinyl and benzothiazolyl modulators AMGEN INC. (US) 2011-06-14 US disclosed
US-20100113522-A1 COMPOUNDS FOR THE MODULATION OF PPARgamma ACTIVITY AMGEN INC. (US) 2010-05-06 US disclosed
WO-2002000633-A1 QUINOLINYL AND BENZOTHIAZOLYL PPAR-GAMMA MODULATORS TULARIK INC. (US) 2002-01-03 WO disclosed
WO-2001000579-A1 COMPOUNDS FOR THE MODULATION OF PPARη ACTIVITY TULARIK INC. (US) 2001-01-04 WO disclosed
CN-1037568-C Phosphosulfonate herbicides ROHM & HAAS (US) 1998-03-04 CN disclosed
CN-1165143-A Phosphosulfonate herbicides ROHM & HAAS (US) 1997-11-19 CN disclosed
CN-1165144-A Phosphosulfonate herbicides ROHM & HAAS (US) 1997-11-19 CN disclosed
EP-0511826-B1 Phosphosulfonate herbicides ROHM & HAAS (US) 1997-07-16 EP disclosed
US-5500405-A Phosphosulfonate herbicides ROHM AND HAAS COMPANY (US) 1996-03-19 US disclosed
US-5272128-A Phosphosulfonate herbicides ROHM AND HAAS COMPANY (US) 1993-12-21 US disclosed
EP-0511826-A2 Phosphosulfonate herbicides ROHM AND HAAS COMPANY (US) 1992-11-04 EP disclosed
US-4507315-A Hypoglycaemic and hypolipidaemic benzamide substituted (1H-) imidazole derivatives and compositions MAY & BAKER LIMITED (GB) 1985-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200308122-A1 NOVEL NON-SYSTEMIC TGR5 AGONISTS GPR119, SSTR5, FFAR3 TRPV4 330/4885RAB9A 3342/4885PKM 2506/4885
US-12630529-B2 GCN2 modulator compounds NR3C1, GCN1, EIF2AK4 TRPV4 2630/4885RAB9A 500/4885PKM 3687/4885
US-20230143059-A1 GCN2 MODULATOR COMPOUNDS EIF2AK4, GPR119, GCN1 TRPV4 2116/4885RAB9A 810/4885PKM 2119/4885
US-11236055-B2 Non-systemic TGR5 agonists SSTR5, GPR119, FFAR3 TRPV4 338/4885RAB9A 3612/4885PKM 2200/4885
US-20100113522-A1 COMPOUNDS FOR THE MODULATION OF PPARgamma ACTIVITY PPARG, PPARA, PPARD TRPV4 2030/4885RAB9A 3138/4885PKM 1261/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.